Skip to content

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency, Intensity, and Functionality: A Single-Arm Study

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency, Intensity, and Functionality: A Single-Arm Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06695156
Enrollment
30
Registered
2024-11-19
Start date
2024-08-28
Completion date
2026-05-30
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine, Migraine With or Without Aura

Keywords

Migraine, Meditation, Transcendental Meditation

Brief summary

This research will explore the effect of the Transcendental Meditation® Technique on migraine intensity and frequency. It will be a single-arm pilot study involving 30 participants recruited from migraine treatment facilities and support groups in the US.

Detailed description

The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will keep a daily migraine diary for 30 days before inclusion in the study, both to assess migraine status and to adhere to study protocols during the study. All the subjects will receive TM instruction, followed by bi-weekly group meetings and one-on-one sessions for 3 months to monitor progress and ensure correct practice.

Interventions

BEHAVIORALMeditation

The objective of this study is to assess the safety, feasibility, and effects of the practice of the Transcendental Meditation technique in adults with migraines. This study will involve 30 male and female participants recruited from migraine treatment facilities and migraine support groups in the US. The study will span three months, with all participants practicing Transcendental Meditation (TM) while continuing their usual lifestyle and medication regimen. Pre-data will be collected through symptom analysis, headache patterns, and evaluation questionnaires. All potential subjects will use a migraine App for 30 days prior to inclusion in the study, both as a means of assessing migraine status and of ability to adhere to study protocols during the study. In addition, all subjects will take the PHQ-9 to screen for levels of depression that might impair participation in the study. All the subjects will receive TM instruction, followed by bi-weekly

Sponsors

Maharishi International University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

It is a pilot study investigating the impact of Transcendental Meditation on migraine as a basis for a larger randomized control study.

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of migraine with or without aura, based on ICHD3 criteria * 4 and above migraine days/month. * · Episodic (4-14) vs chronic migraine (15+) * ≥ one-year history of migraines starting before the age of 50. * ≥ 18 years old or ≤ 60 Years old * Willing to attend follow-up sessions. * Willing to practice TM twice a day for 20 minutes. * Fluent in English. Willing to continue the same medication without any additional medicine In good general health, with no other diseases expected to interfere with the study.

Exclusion criteria

* \> 60 years old or \< 18 Years old * Already practicing Transcendental Meditation. * Pre-diagnosed major systemic illness or unstable medical/psychiatric condition (eg, suicide risk) requiring immediate treatment or that could compromise protocol adherence * Medication overuse headache (MOH) * Current/planned pregnancy or breastfeeding * New prophylactic migraine medicine started within 4 weeks of the screening visit * Unwilling to maintain stable migraine medication dosages * Failure to complete baseline headache logs.

Design outcomes

Primary

MeasureTime frameDescription
Frequency and functionality6 MonthsFrequency and functionality will be measured by the data recorded in the migraine App.
The Migraine Disability Assessment (MIDAS) to measure frequency and functionality.6 Months
Migraine Specific Quality of Life Questionnaire (MSQ), version 2.1 to measure impact on Quality of Life6 Months
Questionnaire (MSQ), version 2.1 to measure impact on functionality.6 months

Countries

United States

Contacts

STUDY_CHAIRDr. Fred T Travis, PhD

Maharishi International University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026